Boston Scientific said it will immediately begin to market its Promus Element drug-eluting stent in the European Union, now that it’s won CE Mark approval for the device.
The news comes just in time for the Natick, Mass.-based medical devices giant, whose deal to put its Promus brand on rival Abbott’s Xience V stent is about to expire. It could also help BSX mitigate the damage to its share of the DES market after recent studies indicated that paclitaxel, the drug it uses to coat its Taxus stent line, is less effective than the Promus Element’s everolimus coating.
Boston Scientific said its putting the Promus Element stent through its paces in the Platinum clinical trial, a 1,500-patient study comparing the device with an earlier, cobalt-chromium alloy Promus model that uses the same drug dose and polymer. A pair of parallel sub-trials will evaluate the Promus Element in small vessels and long lesions.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Food & Drug Administration approval of the Promus Element could come as soon as 2012, the company said, with CE Marking for the Taxus Element expected during the second quarter of 2010. FDA approval for the latter stent is expected some time in 2011.
Boston Scientific shares were trading at $8.17 as of about 10 a.m. Nov. 2, up half a cent or 0.62 percent from the day’s opening price.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.